ONCOGENOMICS
ONCOGENOMICS
MOLECULAR APPROACHES TO CANCER

Edited By

Charles Brenner, Ph.D.
Departments of Genetics and Biochemistry
Norris Cotton Cancer Center
Dartmouth Medical School
Lebanon, New Hampshire

David Duggan, Ph.D.
Translational Genomics Research Institute
Phoenix, Arizona

WILEY-LISS
A JOHN WILEY & SONS, INC., PUBLICATION
This book is dedicated to the patients.
CONTENTS

Contributors xi
Preface xv

Section I  INTRODUCTION

1  AT THE PRECARIOUS CUSP OF ONCOGENOMICS  3
   Charles Brenner

Section II  MOLECULAR PROFILING IN CANCER: DNA, RNA,
   AND PROTEIN

2  GENOME-WIDE SEARCHES FOR MUTATIONS IN HUMAN
   CANCER  17
   Michael R. Stratton, P. Andrew Futreal, and Richard Wooster

3  MOLECULAR CYTOGENETICS: INCREASING RESOLUTION
   USING ARRAY-BASED CGH  37
   Anne Kallioniemi

4  SNPs AND FUNCTIONAL POLYMORPHISMS IN CANCER  57
   Penelope E. Bonnen and David L. Nelson

5  EXPRESSION PROFILING OF BREAST CANCER: FROM
   MOLECULAR PORTRAITS TO CLINICAL UTILITY  77
   Therese Sørlie, Anne-Lise Børresen-Dale, Per E. Lønning, Patrick
   O. Brown, and David Botstein
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>CLASSIFYING HEREDITARY CANCERS AND PHENOCOPIES OF HEREDITARY CANCERS USING EXPRESSION ARRAYS</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Mary B. Daly, Alicia Parlanti, and David Duggan</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>LINKING DRUGS AND GENES: PHARMACOGENOMICS, PHARMACOPROTEOMICS, BIOINFORMATICS, AND THE NCI-60</td>
<td>117</td>
</tr>
<tr>
<td></td>
<td>John N. Weinstein</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>TISSUE MICROANALYSIS: PROFILING CANCER STAGES</td>
<td>139</td>
</tr>
<tr>
<td></td>
<td>Michael A. Tangrea and Michael R. Emmert-Buck</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>PROTEOMICS IN BLADDER CANCER</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>Julio E. Celis, Irina Gromova, Fritz Rank, and Pavel Gromov</td>
<td></td>
</tr>
<tr>
<td>Section III</td>
<td>MODEL SYSTEMS</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>CHEMICAL AND GENETIC METHODS TO VALIDATE TARGETS IN NONMAMMALIAN ORGANISMS</td>
<td>187</td>
</tr>
<tr>
<td></td>
<td>Tia M. Maiolatesi and Charles Brenner</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>MOUSE MODELS OF CANCER</td>
<td>199</td>
</tr>
<tr>
<td></td>
<td>Debrah M. Thompson, Louise van der Weyden, Patrick J. Biggs, Yeun-Jun Chung, and Allan Bradley</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>GENOME-WIDE MODIFIER SCREENS: HOW THE GENETICS OF CANCER PENETRANCE MAY SHAPE THE FUTURE OF PREVENTION AND TREATMENT</td>
<td>255</td>
</tr>
<tr>
<td></td>
<td>Linda D. Siracusa, Karen A. Silverman, Revati Koratkar, Marina Markova, and Arthur M. Buchberg</td>
<td></td>
</tr>
<tr>
<td>Section IV</td>
<td>MOLECULARLY TARGETED DRUGS</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>PROTEIN KINASES AS TARGETS IN CANCER THERAPY: VALIDATED AND EMERGING APPROACHES</td>
<td>293</td>
</tr>
<tr>
<td></td>
<td>Paul Nghiem, Yong-sun Kim, and Stuart L. Schreiber</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>14</td>
<td>RAS SUPERFAMILY-DIRECTED COMPOUNDS</td>
<td>317</td>
</tr>
<tr>
<td></td>
<td>George C. Prendergast</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>CLINOMICS: POSTGENOMIC CANCER CARE</td>
<td>341</td>
</tr>
<tr>
<td></td>
<td>Daniel D. Von Hoff, Haiyong Han, and David Bearss</td>
<td></td>
</tr>
<tr>
<td>Section V</td>
<td>CONCLUSION</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>ONCOGENOMICS AND THE NCI DIRECTOR’S VISION FOR 2015</td>
<td>361</td>
</tr>
<tr>
<td></td>
<td>Andrew C. von Eschenbach</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INDEX</td>
<td>365</td>
</tr>
</tbody>
</table>
This Page Intentionally Left Blank
CONTRIBUTORS

David Bearss, Montigen Pharmaceuticals, Salt Lake City, Utah

Patrick J. Biggs, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Penelope E. Bonnen, Laboratory of Molecular Genetics, Rockefeller University, New York, New York

Anne-Lise Børresen-Dale, Department of Genetics, The Norwegian Radium Hospital, Oslo, Norway

David Botstein, Department of Molecular Biology, Princeton University, Princeton, New Jersey

Allan Bradley, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Charles Brenner, Departments of Genetics and Biochemistry and Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire

Patrick O. Brown, Department of Biochemistry and Howard Hughes Medical Institute, Stanford University, Stanford, California

Arthur M. Buchberg, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Julio E. Celis, Institute of Cancer Biology, The Danish Cancer Society, Copenhagen, Denmark

Yeun-Jun Chung, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Mary B. Daly, Fox Chase Cancer Center, Philadelphia, Pennsylvania

David Duggan, Translational Genomics Research Institute, Phoenix, Arizona

Michael R. Emmert-Buck, Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

P. Andrew Futreal, Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Pavel Gromov, Institute of Cancer Biology, The Danish Cancer Society, Copenhagen, Denmark
Irina Gromova, Institute of Cancer Biology, The Danish Cancer Society, Copenhagen, Denmark

Haiyong Han, Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona

Anne Kallioniemi, Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Finland

Yong-son Kim, Cutaneous Biology Research Center, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts

Revati Koratkar, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Per E. Lønning, Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway

Tia M. Maiolatesi, Departments of Genetics and Biochemistry and Norris Cotton Cancer Center, Lebanon, New Hampshire

Marina Markova, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

David L. Nelson, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas

Paul Nghiem, Cutaneous Biology Research Center, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts

Alicia Parlanti, Myriad Genetics, Salt Lake City, Utah

George C. Prendergast, Lankenau Institute for Medical Research and Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania

Fritz Rank, Laboratory of Clinical Pathology, Diagnostic Center, Rigshospitalet, Copenhagen, Denmark

Stuart L. Schreiber, Department of Chemistry and Chemical Biology, Howard Hughes Medical Institute, Harvard University, Cambridge, Massachusetts

Karen A. Silverman, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Linda D. Siracusa, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Therese Sørlie, Department of Genetics, The Norwegian Radium Hospital, Oslo, Norway

Michael R. Stratton, Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom
CONTRIBUTORS

Michael A. Tangrea, Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Debrah M. Thompson, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Louise van der Weyden, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Andrew C. von Eschenbach, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Daniel D. Von Hoff, Departments of Medicine, Pathology and Molecular and Cellular Biology, Arizona Cancer Center, University of Arizona, Tucson, Arizona; Translational Genomics Research Institute, Phoenix, Arizona

John N. Weinstein, Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Richard Wooster, Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom
This Page Intentionally Left Blank